Studies On Quality Analysis And Toxicity Of Mylabris

Mylabris is the dry body of Mylabris phalerata Pallas or Mylabris cichorii Linnaeus. It's first recorded in ShenNong's Herbal, It was used to cure the disorder of superficial infection and anabrosis. Mylabris is highly poisonous and often causes clinical poisoning, so it always needs to be processed. To improve the safety and stability of the use of Mylabris in clinical medication, In our study, we compared the quality and toxicity of Mylabris before processing and after that. The main content and results are as follows:Parti Studies on Quality Evaluation1. Establish HPLC quantitative determination method for cantharidin, which is the principal component of Mylabris. Compare the cantharidin content in cantharidin pieces of different origins, species and parts. The result shows that the cantharidin content in five different areas of different origins is 0.90%-1.17%, the average is 1.01%. While, it's almost the same in different species. The cantharidin is mainly concentrated in Mylabris's chest and abdomen, there's little cantharidin in its head, foot or wings. It will reduce after being processed.2. Improve the extraction process for cantharidin. The result shows that the total content of cantharidin extracted by CHCI3 and HCL is 1.85 times more than the one extracted by chloroform only. P.S. The total content of cantharidin can show the medicine's toxicity and quality better.Part2 Studies on the Biological Activity and Components Analisis1. Sutdyies on anti-tumor experiments by daubing cantharidin and petroleum ether to their body. The Result shows that2. Qualitative analysis with GC-MS, to get the component of the part which cantharidin and petroleum ether has an effect on. The result shows that, there are ten fatty acids, including seven saturated fatty acids and three unsaturated fatty acids. The saturated fatty acids is myristic acid, palmitic acid, heptadecanoic acid, stearic acid, nonane-decanoic acid, eicosanoic acid and behenic acid, and they are 33%. The unsaturated fatty acids are palmitoleic acid, oleic acid and leinoleic acid, and they are 67%.3. Establish the determination method for the GC content of Mylabris's fatty acids. Take palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid and linolenic acid as indicators, and measure the content of seven fatty acids in cantharidin pieces both before the processing and after that. The result shows that the content of fatty acids almost makes no differences. This method proves to be exact and reliable, so it makes sense to establish the multiple indicator determination method for Mylabris.Part2 Toxicity research1. Vesicate in guinea pigs'ears, take the time, rate and size as indicators, compare the toxicity to skin both before the processing and after that. The result shows that the toxicity of Mylabris reduces after processing, but there's still toxicity on the skin.2. Acute poisoning test on mice, take LD5o and the reaction, and pathology as indicators, compare the toxicity both before the processing and after that. The result shows that infuse medicine into mice's stomach, the toxicity of Mylabris reduces after processing. And the pathology shows target organs are liver and kidney.3. Long poisoning test on mice's liver and kidney, take serum biochemical indicators and pathology as indicates, compare the toxicity to liver and kidney both before the processing and after that, investigate the correlation between toxicity and the content of cantharidin. The result shows that, in case of overdose by mouth, it can cause obvious toxic reaction soon, and the toxicity depends on dose. On other hand, in case of pharmacopoeia dose, there's no obvious toxic reaction. In clinical application, the usage and dosage of Mylabris should be strictly controlled to avoid toxic reaction.